Washington, USA
08048034998
+919359902383
ANTI CANCER MEDICINE

Tishtha 100mg Injection (Nivolumab)| Ernest OncologyExporter to USA, UK, UAE, Australia, Singapore, & South Africa

In stockcod not available
Phone Number

08048034998

Please keep 0 before dialling the number.

Mon-Thu: 10 AM - 2 PM • Fri: 3 PM - 7AM

Other Website Visit our other website
Address Washington , District of Columbia , District of Columbia

Washington, USA, United States, 1

Description

The Professional Guide to Tishtha (Nivolumab) 100mg Injection: Global Immunotherapy Supply As the global medical community adopts biosimilars for cost-effective cancer care, Tishtha (Nivolumab) 100mg Injection has emerged as a vital resource. Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) serves as a specialized pharmaceutical exporter from India, bridging the gap for advanced immunotherapy in the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, Africa, and Asia. What is Tishtha 100 mg? Tishtha is a programmed death receptor-1 (PD-1) blocking antibody. It is the world’s first biosimilar of Nivolumab, offering the same clinical efficacy as the reference biologic. By binding to the PD-1 receptor on T-cells, Tishtha prevents cancer cells from using the PD-1 pathway to hide from the immune system, effectively reactivating the body's natural defenses to destroy tumors. Comprehensive Therapeutic Indications Tishtha 100 mg is utilized in the treatment of a broad spectrum of advanced malignancies: Advanced Melanoma: As a monotherapy or in combination with other agents for unresectable or metastatic skin cancer. Non-Small Cell Lung Cancer (NSCLC): For patients who have progressed during or after platinum-based chemotherapy. Renal Cell Carcinoma (RCC): For patients with advanced kidney cancer who have received prior anti-angiogenic therapy. Classical Hodgkin Lymphoma (cHL): For patients who have relapsed or progressed after autologous stem cell transplant. Squamous Cell Carcinoma of the Head and Neck (SCCHN): For recurrent or metastatic cases. Urothelial Carcinoma: For locally advanced or metastatic bladder cancer. Product Specifications & Administration Technical Specifications Active Ingredient: Nivolumab (10 mg/mL) Strength: 100 mg / 10 mL single-dose vial Manufacturer: Zydus Lifesciences (Zydus Cadila) Form: Sterile, preservative-free, clear to opalescent, colorless to pale yellow solution. Storage: Requires strict cold-chain maintenance at 2Β°C to 8Β°C (36Β°F to 46Β°F). Do not freeze or shake. Mechanism: PD-1 Immune Checkpoint Inhibitor (Monoclonal Antibody). Clinical Usage and Dosage Administration: Tishtha must be administered as an Intravenous (IV) Infusion by a qualified healthcare professional. The infusion typically lasts 30 to 60 minutes. Dosing Schedules: Depending on the cancer type, dosing may be weight-based (e.g., 3 mg/kg) or fixed (e.g., 240 mg every 2 weeks or 480 mg every 4 weeks). Infusion Safety: Vials should be inspected for particulate matter before use. If not used immediately, the diluted solution can be stored refrigerated for up to 24 hours. Safety and Side Effects Immune-mediated adverse reactions (irAEs) are possible because the drug activates the immune system. Common: Fatigue, rash, musculoskeletal pain, and upper respiratory tract infections. Serious: Inflammation of the lungs (pneumonitis), liver (hepatitis), or colon (colitis). Patients are monitored closely for these symptoms throughout therapy. Global Distribution Excellence by Ernest Oncology Exporting high-value biologics like Tishtha 100mg requires a sophisticated logistics network. Validated Cold-Chain Logistics: We utilize specialized thermal packaging and real-time temperature tracking to ensure the 100 mg vials reach Singapore, London, or Dubai without loss of potency. Bulk Supplier Efficiency: We cater to large-scale hospital tenders and oncology distributors in South Africa, Australia, and the Middle East. Regulatory Compliance: Our team manages all export documentation and international shipping protocols, ensuring smooth customs clearance in Europe and the USA. πŸ“ž Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com πŸ“§ Email exports@ernestpharmaceuticals.com πŸ“¦ Business Type Exporter | Bulk Supplier | Distributor πŸ“² WhatsApp +91 93599 02383 πŸ”— https://wa.me/919359902383

Keywords

Other Products

view all

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

The Comprehensive Guide to Temalieva 250 mg Capsules In precision neuro-oncology and general cancer care, Temalieva 250 mg capsules (containing the active ingredient Temozolomide) stand as a critical therapeutic agent for treating aggressive brain tumors. As a premier pharmaceutical exporter from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this life-saving medication is accessible to hospitals, pharmacies, and healthcare systems in London, the UK, the USA, Australia, and South Africa with full regulatory compliance. Product SpecificationsFeatureDetailBrand NameTemalieva 250 (Temozolomide Capsules IP)Strength250 mgDosage FormOral Hard Gelatin CapsulePrimary IndicationGlioblastoma multiforme & anaplastic astrocytomaStorageStore below 25Β°C in a cool, dry place. Protect from moisture and light. Mechanism of Action: How It Works DNA Alkylation: Once ingested, Temozolomide readily crosses the blood-brain barrier. At physiological pH, it is converted into the active compound MTIC. Interfering with Replication: MTIC methylates DNA at specific locations, which causes DNA strand breaks and cross-linking. This process inhibits the multiplication and growth of rapidly dividing cancer cells, ultimately leading to programmed cell death (apoptosis). Therapeutic Indications & Administration Glioblastoma Multiforme (GBM): Used for newly diagnosed GBM patients in combination with focal radiation therapy, followed by maintenance therapy. Refractory Anaplastic Astrocytoma: Treatment for patients experiencing tumor recurrence or progression after standard therapy. Administration Guidelines Dosing Schedule: Dosing is calculated based on the patient's body surface area (BSA). Ingestion: Swallow the capsules whole with a full glass of water. Do not open, crush, or chew the capsule contents to prevent exposure to the active drug. Minimizing Side Effects: To reduce the incidence of nausea and vomiting, patients are often advised to take the medication on an empty stomach or at bedtime. Clinical Side Effects & Safety Profile Common Side Effects: Nausea, vomiting, headache, fatigue, constipation, and loss of appetite. Prophylactic antiemetics are frequently prescribed. Myelosuppression: The most serious clinical risk is a decrease in bone marrow function, which leads to reduced white blood cell and platelet counts. This increases susceptibility to infections and bruising or bleeding. Liver Function: Patients should undergo regular liver function tests (LFTs) due to the potential for hepatotoxicity. Contraindications: It is contraindicated during pregnancy and breastfeeding due to the risk of fetal harm. Male patients must use effective contraception during treatment and for at least 3 months afterward. Why Source from Ernest Oncology? United Kingdom (London): Providing high-quality, cost-effective generic alternatives for private and public healthcare systems. USA: Delivering bulk quantities that comply with international documentation and safety standards. Australia: Facilitating secure access through compliant supply channels such as the β€œSpecial Access Schemeβ€œ (SAS). South Africa: Bridging critical gaps in the oncology market with affordable, high-tier pharmaceutical exports from India. πŸ“ž Contact Ernest Oncology β€” Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] πŸ“¦ Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com πŸ“§ Email: exports@ernestpharmaceuticals.com πŸ“² WhatsApp: +91 93599 02383 πŸ”— Direct Link: https://wa.me/919359902383

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

Comprehensive Product Authority Guide: Temalieva 20mg (Temozolomide) Temalieva 20mg, formulated with the active pharmaceutical ingredient Temozolomide, is a potent oral alkylating antineoplastic agent. It is widely recognized and utilized in neuro-oncology for the treatment of aggressive forms of brain tumors. 1. Advanced Mechanism of Action DNA Methylation: MTIC works by methylating DNA at the O6 and N7 positions of guanine. Cell Cycle Arrest: This methylation damages the genetic material of cancer cells, leading to DNA double-strand breaks and inducing apoptosis (programmed cell death) in rapidly dividing tumor cells. Blood-Brain Barrier Penetration: Because it is highly lipophilic, it crosses the blood-brain barrier easily, making it uniquely effective against primary and secondary brain malignancies. 2. Therapeutic Indications Glioblastoma Multiforme (GBM): Administered in combination with focal radiotherapy as an initial treatment, followed by maintenance therapy to prevent recurrence. Anaplastic Astrocytoma: Prescribed for patients with refractory or progressive malignant glioma, including anaplastic astrocytoma. Other Malignancies: Clinical evaluation has shown efficacy in certain systemic cancers and targeted neuro-oncology protocols. 3. Dosage and Administration Strength: Available as 20mg oral capsules. Administration Protocol: To minimize nausea and ensure consistent bioavailability, the medication should be taken consistently (either always on an empty stomach or always with a light meal) at the same time each day. Handling Instructions: Capsules must be swallowed whole with a full glass of water. They should not be opened, chewed, crushed, or split, as the contents are highly cytotoxic. 4. Safety Profile and Side Effect Management Common Side Effects: Nausea, vomiting, fatigue, headache, and constipation. Hematological Effects: Myelosuppression (reduced red/white blood cell and platelet counts), which increases the risk of serious infections. Monitoring: Frequent complete blood counts (CBC) and liver function tests are recommended throughout the treatment cycle. Why Source from Ernest Oncology? Ernest Oncologyβ€”a specialized division of Ernest Pharmaceutical Pvt. Ltd.β€”is a trusted global exporter, bulk supplier, and distributor. We facilitate the secure, temperature-controlled delivery of life-saving specialty pharmaceuticals worldwide, bridging the gap between state-of-the-art manufacturing in India and the requirements of global healthcare networks. πŸ“ž Contact Ernest Oncology β€” Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] πŸ“¦ Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com πŸ“§ Email: exports@ernestpharmaceuticals.com πŸ“² WhatsApp: +91 93599 02383 πŸ”— Direct Link: https://wa.me/919359902383

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

The Comprehensive Guide to Leuprolide 22.5 mg Injection For healthcare providers, clinics, and pharmaceutical distributors globally, Leuprolide 22.5 mg Injection is a critical, long-acting medication used to manage advanced hormone-dependent conditions. As a leading pharmaceutical exporter and bulk supplier from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this vital medication reaches medical facilities across London, New York, Sydney, Johannesburg, and the broader global market with full regulatory compliance. Product Specifications Brand Name: Ernest-Oncology (Leuprolide Acetate) Strength: 22.5 mg Dosage Form: Depot Suspension for Injection (Subcutaneous or Intramuscular) Primary Indication: Advanced prostate cancer, endometriosis, and uterine fibroids. Storage: Store at room temperature (20Β°C to 25Β°C), protect from light and moisture. Mechanism of Action: How It Works Initial Stimulation: Upon initial administration, it briefly increases the levels of certain hormones (like testosterone in men and estrogen in women). Down-Regulation: With continuous administration, it desensitizes the pituitary gland. This stops the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Hormone Suppression: Consequently, it drastically reduces the levels of testosterone or estrogen in the body, which effectively slows or stops the growth of hormone-dependent tumors and tissues. Therapeutic Indications & Administration Advanced Prostate Cancer: Palliative treatment to reduce testosterone levels and suppress tumor progression. Endometriosis & Uterine Fibroids: Relieving pelvic pain and shrinking tissue growths in female patients. Administration: * Route: Administered as a subcutaneous or intramuscular injection by a qualified healthcare professional. Frequency: Given once every 3 months due to the extended-release depot delivery system. Clinical Side Effects & Safety Profile Hormone-Suppression Effects: Hot flashes, night sweats, fatigue, mood changes, and decreased sex drive. Bone Mineral Density Loss: Long-term use can lower bone density, carrying a risk of osteoporosis or bone fractures. Initial Tumor Flare: In the first few weeks, prostate cancer symptoms (like bone or nerve pain) may temporarily worsen before improving. Serious Warnings: Rare risks include cardiovascular events (heart attack, stroke), QT prolongation, and severe skin reactions like Stevens-Johnson syndrome. Contraindications: Contraindicated during pregnancy and breastfeeding due to the high risk of fetal harm. Why Source from Ernest Oncology? United Kingdom (London): Supplying cost-effective, high-quality oncology solutions for specialized clinics and hospitals. USA: Delivering bulk quantities that meet international safety, regulatory, and documentation standards. Australia: Ensuring stable access through established supply chains. South Africa: Bridging critical gaps in the oncology market with reliable, top-tier pharmaceutical exports from India. πŸ“ž Contact Ernest Oncology β€” Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] πŸ“¦ Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com πŸ“§ Email: exports@ernestpharmaceuticals.com πŸ“² WhatsApp: +91 93599 02383 πŸ”— Direct Link: https://wa.me/919359902383